Nadia Forghani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nadia Forghani has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ali Shakeri Abroudi
Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
1 shared publication - Danial Hashemi Karoii
Department of Stem Cells and Cancer, College of Biotechnology, Amol University of Special Modern Technologies, Amol, 46158-63111, Iran; Department of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran
1 shared publication - Ehsan HasanZadeh
Department of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran
1 shared publication - Hamoon Baghaei
Pediatric Urology and Regenerative Medicine Research Center, Gene, Cell and Tissue Research Institute, Children’s Medical Center, Tehran University of Medical University, Tehran, Iran
1 shared publication - Melika Djamali
Department of Biology, Faculty of Science, Tehran University, Tehran, Iran
1 shared publication - Sana Shafaeitilaki
Department of Cellular and Molecular Biology, Islamic Azad University, Sari Branch, Sari, Iran
1 shared publication
Latest Publications
- Open Access
- 13 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-28
Analysis of microarray and single-cell RNA-seq identifies gene co-expression, cell–cell communication, and tumor environment associated with metabolite interconversion enzyme in prostate cancer
Background Prostate cancer (PCa) is the second most common malignant neoplasm in males and is the fifth leading cause of cancer-related mortality. Due to the use of prostate-specific antigen (PSA) screening and improved biopsy techniques, persons identified with early-stage prostate cancer often have a positive prognosis after comprehensive treatment. Nonetheless, prostate cancer is a latent illness that may present as an asymptomatic tumor in individuals aged 20–30. The overall survival (OS) of men with advanced PCa is significantly diminished. Consequently, there is an immediate want for innovative, accurate biomarkers to detect early prostate cancer. Methods This research analyzed the interaction network of differentially expressed genes (DEGs) related to metabolite interconversion enzymes in PCa by gene expression microarray data, single-cell RNA sequencing, oncogenes, and tumor suppressor genes (TSGs) utilizing bioinformatics techniques. This kind of analysis has not been documented in prior studies. Results We then used a dataset acquired by the Cancer Genome Atlas (TCGA) to confirm our findings. Genes including CYP3A5, PDE8B, AOX1, BNIPL, FADS2, RRM2, ALDH3B2, and GSTM2 may be significant in the diagnosis and treatment of PCa. Conclusion Our objective was to provide new perspectives on the molecular properties and pathways of DEGs in PCa and to uncover potential biomarkers that play a crucial role in the genesis and progression of PCa.
- 13 February 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-28
Open AccessAnalysis of microarray and single-cell RNA-seq identifies gene co-expression, cell–cell communication, and tumor environment associated with metabolite interconversion enzyme in prostate cancer
Background Prostate cancer (PCa) is the second most common malignant neoplasm in males and is the fifth leading cause of cancer-related mortality. Due to the use of prostate-specific antigen (PSA) screening and improved biopsy techniques, persons identified with early-stage prostate cancer often have a positive prognosis after comprehensive treatment. Nonetheless, prostate cancer is a latent illness that may present as an asymptomatic tumor in individuals aged 20–30. The overall survival (OS) of men with advanced PCa is significantly diminished. Consequently, there is an immediate want for innovative, accurate biomarkers to detect early prostate cancer. Methods This research analyzed the interaction network of differentially expressed genes (DEGs) related to metabolite interconversion enzymes in PCa by gene expression microarray data, single-cell RNA sequencing, oncogenes, and tumor suppressor genes (TSGs) utilizing bioinformatics techniques. This kind of analysis has not been documented in prior studies. Results We then used a dataset acquired by the Cancer Genome Atlas (TCGA) to confirm our findings. Genes including CYP3A5, PDE8B, AOX1, BNIPL, FADS2, RRM2, ALDH3B2, and GSTM2 may be significant in the diagnosis and treatment of PCa. Conclusion Our objective was to provide new perspectives on the molecular properties and pathways of DEGs in PCa and to uncover potential biomarkers that play a crucial role in the genesis and progression of PCa.